Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by valentinemassonon Aug 21, 2020 4:08pm
162 Views
Post# 31440107

RE:RE:Just thinking out loud....

RE:RE:Just thinking out loud....
gpe2005 wrote: In my opinion, SZLS has not been able to show the ability to sell their product. ColonSentry has been on the market for some time now with very little success. Mercer has been supporting the COVID testing but till sending thier cancer clients to ColonSentry's competitors. The idea that single cancer testing is being held back waiting for Aristotle holds no water. That's like when Apple came out with the first I Phone, Steve saying "let's wait till next year when we have the next generation I Phone". Why they can't seem to get ColonSentry off the ground is another question.


 Colon Sentry was launched at a time of doubt in the product`s ability to be successful . As of late, liquid biopsies are gaining ground. Why? In Aristotle, Colon Sentry has merged into it with amendments. Aristotle is able to detect for example polyps in the colon on the loeft, or right side , the right being deadly. Liquid biopsies are just coming to light now, in that they ae able to detect, pinpoint, and rule stage 1,2,3 or 4 and where in the body it came from, without invasive techniques. Insurance companies would much rather pay for a blood test , than an endoscopy, and this all being in the case of colon. Add another 9 including the deadly pancreatic cancer. AstraZeneca and
Merck
are 2 entities that support this technique moving forward.

  Link Here Liquid Biopsies

 More Info

Bullboard Posts